Article
Immunology
Antonia Morga, Tomomi Kimura, Qi Feng, Nigel Rozario, Jason Schwartz
Summary: This study evaluated compliance to pneumococcal vaccination recommendations for adults aged >= 65 years and with high-risk conditions. The findings showed low compliance rates and suggested the need for additional efforts to improve vaccination rates to reduce the incidence and burden of pneumococcal disease.
Review
Biotechnology & Applied Microbiology
Finlay Pilcher, Jan Kirk Carney, Gary S. Stein
Summary: This article discusses the importance of the Human Papillomavirus (HPV) vaccine in preventing various types of cancers. Despite its effectiveness, HPV vaccination rates in rural areas are lower, leading to higher rates of cervical cancer incidence and mortality. The current interventions are limited, thus a multi-component peer-based approach, including school-based vaccination and awareness, parental involvement, and stakeholder engagement, is recommended to increase HPV vaccination in rural areas.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Immunology
Matthew Tunis, Shelley Deeks, Robyn Harrison, Caroline Quach, Shainoor Ismail, Marina Salvadori, Bryna Warshawsky, Kelsey Young, Christine Mauviel, Erin Henry
Summary: The COVID-19 pandemic has posed challenges to traditional vaccine guidance systems. Canada's National Advisory Committee on Immunization (NACI) and Public Health Agency of Canada (PHAC) have made various adaptations in structure, technology, communication, and research to provide timely and evidence-based guidance during the pandemic. These adaptations serve as a roadmap for future pandemic vaccine programs and highlight the crucial role of NITAGs in complementing regulatory structures in public health vaccine guidance during pandemics.
Editorial Material
Surgery
Tara C. Anderson, Nina B. Masters, Angela Guo, Leah Shepersky, Andrew J. Leidner, Grace M. Lee, Camille N. Kotton, Kathleen L. Dooling
Summary: The Advisory Committee on Immunization Practices (ACIP) has recommended the use of two doses of Zoster Vaccine Recombinant, Adjuvanted (RZV) for the prevention of herpes zoster and complications in immunosuppressed adults. RZV is the first approved vaccine for immunocompromised individuals, providing the potential to lower the incidence and complications of herpes zoster among transplant candidates and recipients.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Article
Public, Environmental & Occupational Health
Yimeng Mao, Yuchen Zhao, Lingyun Zhang, Jie Li, Abu S. Abdullah, Pinpin Zheng, Fan Wang
Summary: This study aimed to assess the frequency and factors associated with healthcare providers' (HCPs) recommendations for HPV vaccination. Results showed that only 30.2% of participants frequently recommended HPV vaccination. Factors associated with a higher recommendation frequency included female sex, employment in obstetrics or gynecology departments and community health service centers, and higher knowledge of HPV. Factors such as perceiving no obligation to provide recommendations and difficulties in discussing sexual topics were correlated with less frequent recommendations. Employment in a community health service center was the strongest factor associated with the frequency of HCPs' recommendations for HPV vaccination.
FRONTIERS IN PUBLIC HEALTH
(2023)
Review
Immunology
Lauri E. Markowitz, Melanie Drolet, Rayleen M. Lewis, Philippe Lemieux-Mellouki, Norma Perez, Mark Jit, Julia M. Brotherton, Gina Ogilvie, Aimee R. Kreimer, Marc Brisson
Summary: This study provides a systematic literature review on the effectiveness of HPV vaccines. It highlights the biases in observational studies and the need for further research to obtain valid effectiveness estimates.
Article
Health Care Sciences & Services
C. Joseph Ross Daval, Ameet Sarpatwari, Aaron S. Kesselheim
Summary: Controversy arose when FDA approved the Alzheimer's disease drug aducanumab despite negative advisory committee vote. A review of all FDA advisory committee referrals for new drugs between 2010 and 2021 revealed that negatively reviewed drugs were approved about once a year. Variability in voting questions was observed, suggesting the need for reforms to improve public confidence in the FDA approval process.
Article
Public, Environmental & Occupational Health
Jennifer P. Collins, Edward T. Ryan, Karen K. Wong, Matthew F. Daley, Adam J. Ratner, Grace D. Appiah, Pablo J. Sanchez, Bruce J. Gutelius
Summary: This report summarizes the recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) for the use of CVD 103-HgR vaccine in the United States. ACIP recommends the use of CVD 103-HgR vaccine for travelers to areas with active cholera transmission to prevent cholera.
MMWR RECOMMENDATIONS AND REPORTS
(2022)
Review
Pharmacology & Pharmacy
S. G. Antimisiaris, A. Marazioti, M. Kannavou, E. Natsaridis, F. Gkartziou, G. Kogkos, S. Mourtas
Summary: Localized or topical drug administration, in combination with nanoparticulate formulations like liposomes, can offer advantages such as prolonged retention of high drug loads, controlled release, reduced side effects, and increased protection from harsh environments. Targeted liposomal formulations may enhance these therapeutic advantages in drug delivery.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Review
Medicine, General & Internal
Julia S. S. Gillette, Elaina J. J. Wang, Richard S. S. Dowd, Steven A. A. Toms
Summary: Glioblastoma multiforme (GBM) is a common malignant brain tumor with a poor prognosis and high recurrence rate. Immunotherapies have shown promise in treating hematological malignancies, but their effectiveness in GBM is limited by unique immunosuppressive factors. However, research has shown that combinatorial immunotherapies targeting immune processes in GBM have had promising results. This review aims to discuss the immune resistance in GBM and summarize the current evidence and outcomes of treatments to overcome GBM's resistance to immunotherapy.
FRONTIERS IN MEDICINE
(2023)
Article
Oncology
Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, Eva Munoz-Couselo, Carolina Ortiz, Roger Paredes, Daniel Podzamczer, Jose Luis Manzano, Jose Molto, Boris Revollo, Cristina Carrera, Lourdes Mateu, Sara Fancelli, Enrique Espinosa, Bonaventura Clotet, Javier Martinez-Picado, Pablo Cerezuela, Ainara Soria, Ivan Marquez, Mario Mandala, Alfonso Berrocal
Summary: Cancer immunotherapy based on checkpoint inhibitors has shown durable clinical benefit in melanoma and other tumors. However, treating cancer in patients with chronic infections or immunosuppression requires a multidisciplinary approach to reduce the risk of complications.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Caitlin Swift, Aditi Dey, Harunor Rashid, Katrina Clark, Ramesh Manocha, Julia Brotherton, Frank Beard
Summary: Australia has been a leader in HPV vaccination, implementing a national program since 2007. The program has recently transitioned to a 2-dose schedule and has been well accepted by schools and students, reducing costs and resource requirements. However, completion rates have not increased as anticipated due to dosing intervals and limited opportunities for catch-up vaccination. Vaccine hesitancy is not currently a major issue but remains a potential threat. Measures to optimize the program's impact and address potential barriers are important.
Review
Public, Environmental & Occupational Health
Sharvina Ramesh Rao, Nirmala Kampan, Kah Teik Chew, Mohamad Nasir Shafiee
Summary: Since 2010, Malaysia has implemented the HPV immunization program for 13-year-old female students, which has been successful. However, the closure of schools during the COVID-19 pandemic in 2020 resulted in a large number of students missing their vaccinations. This could lead to an increase in cases of cervical cancer and genital warts in the future. Therefore, a well-organized catch-up vaccination program is crucial.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Immunology
Alpamys Issanov, Mohammad Ehsanul Karim, Gulzhanat Aimagambetova, Trevor J. B. Dummer
Summary: This study aimed to evaluate the association between HPV vaccination and HPV-related cancers among US adults. While no statistically significant association was found, the results suggest that vaccinated adults may have lower odds of developing HPV-related cancers.
Article
Public, Environmental & Occupational Health
Gabriela Paz-Bailey, Laura Adams, Joshua M. Wong, Katherine A. Poehling, Wilbur H. Chen, Veronica McNally, Robert L. Atmar, Stephen H. Waterman
Summary: Dengue is a vectorborne infectious disease caused by closely related dengue viruses, transmitted mainly by Aedes mosquitoes. The Dengvaxia vaccine is recommended by ACIP for children aged 9-16 with previous dengue infection in endemic areas, as it is safe and effective in preventing severe dengue. Prior natural infection is important, as vaccination may increase the risk of severe dengue in individuals experiencing their first natural infection after vaccination.
MMWR RECOMMENDATIONS AND REPORTS
(2021)